The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers

European Journal of Clinical Pharmacology

Volumn 69, Issue 7, 2013, Pages 1423-1428

  Yamada, Satoshi ^a   Shiohira, Hideo ^a   Yasui Furukori, Norio ^b   Tateishi, Tomonori ^c   Akamine, Yumiko ^a   Uno, Tsukasa ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

Author keywords

(R) 5 hydroxyomeprazole; (R) omeprazole; (S) 5 hydroxyomeprazole; (S) omeprazole; CYP2C19; Hydroxylation index

Indexed keywords

5 HYDROXYOMEPRAZOLE; CYTOCHROME P450 2C19; OMEPRAZOLE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; JAPANESE; NORMAL HUMAN; PRIORITY JOURNAL;

ALLELES; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; EXONS; GENETIC ASSOCIATION STUDIES; HUMANS; HYDROXYLATION; JAPAN; METABOLIC DETOXICATION, PHASE I; OMEPRAZOLE; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; STEREOISOMERISM;

EID: 84879088492     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1480-1     Document Type: Article

References (31)

1. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
2. Andersson T, Weidolf L (2008) Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 28:263-279
3. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L (2001) Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40:411-426
4. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH (2006) The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta- analysis. Am J Gastroenterol 101:1467-1475
5. Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K, Ishizaki T, Hishida A (2007) Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 81:521-528
6. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69:158-168
7. Schwab M, Schaeffeler E, Klotz U, Treiber G (2004) CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 76:201-209
8. Olbe L, Carlsson E, Lindberg P (2003) A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2:132-139
9. Mohammad M, Amir HDJ, Ahmad S, Neda M, Farinaz T (2010) A randomized controlled trial: Efficacy and safety of azathromycin, ofloxacin, bismutu and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. Helicobacter 15:154-159
10. Ogawa R, Echizen H (2010) Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 1:509-533
11. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T (1993) Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266:52-59
12. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Identification of human liver cytochrome P450 isoform mediating secondary omeprazole metabolism. Br J Clin Pharmacol 35:597-604
13. Äbelö A, Andersson T, Antonsson M, Naudot AK, Skanberg I, Weidolf L (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzyme. Drug Metab Dispos 28:966-972
14. Uno T, Niioka T, Hayakari M, Yasui-Furukori N, Sugawara K, Tateishi T (2007) Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur J Clin Pharmacol 63:143-149
15. Shimizu M, Uno T, Niioka T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T (2006) Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. J Chromatogr B Analyt Technol Biomed Life Sci 832:241-248
16. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, Yoshioka S, Irie S, Amamoto T, Nakamura K, Nakano S, Higuchi S (1996) Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 59:647-653
17. Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, Iimori E, Sakai T, Otsubo K, Higuchi S (1999) Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Br J Clin Pharmacol 47:115-119
18. Niioka T, Uno T, Sugimoto K, Sugawara K, Hayakari M, Tateishi T (2007) Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. Eur J Clin Pharmacol 63:1031-1038
19. Rosemary J, Adithan C, Padmaja N, Shashindran CH, Gerard N, Krishnamoorthy R (2005) The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians. Eur J Clin Pharmacol 61:19-23
20. Yin OQ, Tomlinson B, Chow AH, Waye MM, Chow MS (2004) Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J Clin Pharmacol 44:582-589
21. Shiohira H, Yasui-Furukori N, Yamada S, Tateishi T, Akamine Y, Uno T (2012) Hydroxylation of R(+)- and S(-)-Omeprazole after Racemic Dosing are Different among the CYP2C19 Genotypes. Pharm Res 29:2310-2316
22. Zhou HH, Anthony LB, Wood AJ, Wilkinson GR (1990) Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 30:471-475
23. Feng HJ, Huang SL, Wang W, Zhou HH (1998) The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 45:27-29
24. Zhou HH (2001) CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin Chim Acta 313:203-208
25. Wedlund PJ, Aslanian WS, Jacqz E, McAllister CB, Branch RA, Wilkinson GR (1985) Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther 234:662-669
26. Sugimoto K, Uno T, Yamazaki H, Tateishi T (2008) Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 65:437-439
27. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113
28. Shiohira H, Yasui-Furukori N, Tateishi T, Uno T (2011) Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes. J Chromatogr B Analyt Technol Biomed Life Sci 879:2465-2470
29. Tybring G, Böttiger Y, Widén J, Bertilsson L (1997) Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 62:129-137
30. Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T (2004) Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57:487-494
31. Li X, Weidolf L, Simonsson R, Andersson TB (2005) Enantiomer/Enantiomer interaction between the S- and R-isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther 315:777-787